12:00 AM
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aridol mannitol regulatory update

FDA's Pulmonary-Allergy Drugs Advisory Committee supported approval of Aridol mannitol powder inhalation test from Pharmaxis to assess bronchial hyperresponsiveness (BHR) to aid in the diagnosis of patients six years of age and older with symptoms of asthma or suggestive of asthma. The panel voted 12-3, with one abstention, to support approval of Aridol for patients 18 years and older; 14-2 to...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >